Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Lymphoma: chemotherapy vs. bendamustine

Mathias Rummel • 20 Jun 2017
ASCO 2017
Non-Hodgkin Lymphoma Bendamustine Rituximab

Mathias Rummel, MD, PhD from Justus Liebig University, Giessen, Germany presents the results of a long-term study initiated comparing CHOP-rituximab (CHOP-R) therapy to the combined therapy of bendamustine and rituximab in patients with lymphoma. The study showed that progression-free survival (PFS) was better in the bendamustine arm. The data presented at ASCO 2017 included mature overall survival (OS) data with a median of 10 years follow-up.
Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.

More from Mathias Rummel

4:55
StiL NHL7 MAINTAIN results shed light on B-R upfront and R-maintenance
Mathias Rummel • 7 Dec 2019
2:43
Reporting positive treatment outcomes with bendamustine + rituximab in indolent lymphomas
Mathias Rummel • 21 Jun 2017
1:16
Investigating alternative treatments for non-reponsive lymphoma patients
Mathias Rummel • 20 Jun 2017
7:50
Bendamustine for the treatment of non-Hodgkin lymphoma
Mathias Rummel • 5 Sep 2014

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals